An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging
18F-PSMA-1007 PET/CT imaging is increasingly used for the diagnosis, staging, and efficacy assessment of patients with prostate cancer. Compared with other PSMA tracers, 18F-PSMA-1007 is mainly cleared by the liver and bile and has lower urinary clearance, thus allowing a better assessment of the le...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1238333/full |
| _version_ | 1797730765220347904 |
|---|---|
| author | Jun Dang Yutang Yao Yingchun Li Xiaofei Tan Zhenyan Ye Yi Zhao Shiwei Qing Ying Kou Xiao Jiang Hao Lu Shirong Chen Meng Zhao Zhuzhong Cheng |
| author_facet | Jun Dang Yutang Yao Yingchun Li Xiaofei Tan Zhenyan Ye Yi Zhao Shiwei Qing Ying Kou Xiao Jiang Hao Lu Shirong Chen Meng Zhao Zhuzhong Cheng |
| author_sort | Jun Dang |
| collection | DOAJ |
| description | 18F-PSMA-1007 PET/CT imaging is increasingly used for the diagnosis, staging, and efficacy assessment of patients with prostate cancer. Compared with other PSMA tracers, 18F-PSMA-1007 is mainly cleared by the liver and bile and has lower urinary clearance, thus allowing a better assessment of the lesions around the bladder. However, there were some patients who showed an obvious concentration of the 18F-PSMA-1007 in the bladder, which may affect the observation of peripheral lesions, but the mechanism of this change is unknown. The aim of this study was to explore the cause of bladder 18F-PSMA-1007 concentration by assessing the clinical and imaging characteristics of 18F-PSMA-1007 PET/CT scans. A total of 284 patients were included in this retrospective study, and their clinical characteristics such as age, height, weight, Gleason score, metastases, different treatment methods, the level of liver and kidney function, PSA level, and imaging characteristics such as 18F-PSMA-1007 injected activity, the interval between injection to scan, physiological distribution (parotid gland, kidney, liver, spleen, intestine, obturator internus), pathological distribution (prostate lesions, metastases) were collected, and were compared after subgrouping using bladder urine SUVmax. This study showed that the distribution of bladder 18F-PSMA-1007 was not correlated with the above clinical and imaging characteristics, so further studies are needed to find the explanations, and thus to improve the disease assessment of this type of prostate cancer patients. |
| first_indexed | 2024-03-12T11:49:00Z |
| format | Article |
| id | doaj.art-c85187a2fe6941f9a97a5f656e37a619 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-12T11:49:00Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-c85187a2fe6941f9a97a5f656e37a6192023-08-31T11:45:16ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-08-011010.3389/fmed.2023.12383331238333An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imagingJun Dang0Yutang Yao1Yingchun Li2Xiaofei Tan3Zhenyan Ye4Yi Zhao5Shiwei Qing6Ying Kou7Xiao Jiang8Hao Lu9Shirong Chen10Meng Zhao11Zhuzhong Cheng12Department of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine and Radiotherapy, Air Force Hospital of Western Theater Command, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China18F-PSMA-1007 PET/CT imaging is increasingly used for the diagnosis, staging, and efficacy assessment of patients with prostate cancer. Compared with other PSMA tracers, 18F-PSMA-1007 is mainly cleared by the liver and bile and has lower urinary clearance, thus allowing a better assessment of the lesions around the bladder. However, there were some patients who showed an obvious concentration of the 18F-PSMA-1007 in the bladder, which may affect the observation of peripheral lesions, but the mechanism of this change is unknown. The aim of this study was to explore the cause of bladder 18F-PSMA-1007 concentration by assessing the clinical and imaging characteristics of 18F-PSMA-1007 PET/CT scans. A total of 284 patients were included in this retrospective study, and their clinical characteristics such as age, height, weight, Gleason score, metastases, different treatment methods, the level of liver and kidney function, PSA level, and imaging characteristics such as 18F-PSMA-1007 injected activity, the interval between injection to scan, physiological distribution (parotid gland, kidney, liver, spleen, intestine, obturator internus), pathological distribution (prostate lesions, metastases) were collected, and were compared after subgrouping using bladder urine SUVmax. This study showed that the distribution of bladder 18F-PSMA-1007 was not correlated with the above clinical and imaging characteristics, so further studies are needed to find the explanations, and thus to improve the disease assessment of this type of prostate cancer patients.https://www.frontiersin.org/articles/10.3389/fmed.2023.1238333/fullprostate cancer18F-PSMA-1007PETbladder uptakepositron emission tomography |
| spellingShingle | Jun Dang Yutang Yao Yingchun Li Xiaofei Tan Zhenyan Ye Yi Zhao Shiwei Qing Ying Kou Xiao Jiang Hao Lu Shirong Chen Meng Zhao Zhuzhong Cheng An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging Frontiers in Medicine prostate cancer 18F-PSMA-1007 PET bladder uptake positron emission tomography |
| title | An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging |
| title_full | An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging |
| title_fullStr | An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging |
| title_full_unstemmed | An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging |
| title_short | An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET/CT imaging |
| title_sort | exploratory study of unexplained concentration of 18f psma 1007 in the bladder for prostate cancer pet ct imaging |
| topic | prostate cancer 18F-PSMA-1007 PET bladder uptake positron emission tomography |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1238333/full |
| work_keys_str_mv | AT jundang anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT yutangyao anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT yingchunli anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT xiaofeitan anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT zhenyanye anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT yizhao anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT shiweiqing anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT yingkou anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT xiaojiang anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT haolu anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT shirongchen anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT mengzhao anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT zhuzhongcheng anexploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT jundang exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT yutangyao exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT yingchunli exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT xiaofeitan exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT zhenyanye exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT yizhao exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT shiweiqing exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT yingkou exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT xiaojiang exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT haolu exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT shirongchen exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT mengzhao exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging AT zhuzhongcheng exploratorystudyofunexplainedconcentrationof18fpsma1007inthebladderforprostatecancerpetctimaging |